Citations (167)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Nisha Pippal, Sumita Halder, Shruti Srivastava, Rajarshi Kar, Rachna Gupta & Almeida Edelbert Anthonio. (2022) Correlation between telomere length and efficacy of oral and long-acting injectable antipsychotics on severity and cognitive impairment of schizophrenia. International Journal of Psychiatry in Clinical Practice 26:2, pages 157-164.
Read now
Read now
Maddi Gervasio, Avery Beatty, Brian Kavanaugh, Mary Kathryn Cancilliere & Karen Holler. (2022) The association between neurocognition and sexual abuse within a children’s psychiatric inpatient program. The Clinical Neuropsychologist 36:1, pages 189-206.
Read now
Read now
Jonathan Flintoff, James P Kesby, Dan Siskind & Thomas HJ Burne. (2021) Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential. Expert Opinion on Investigational Drugs 30:8, pages 877-891.
Read now
Read now
Kate Walker, Chris Griffiths, Jen Yates & Birgit Völlm. (2021) Service provision for older forensic mental health patients: a scoping review of the literature. The Journal of Forensic Psychiatry & Psychology 32:1, pages 29-50.
Read now
Read now
Erin J. Shumlich, Graham J. Reid, Megan Hancock & Peter N. S. Hoaken. (2019) Executive Dysfunction in Criminal Populations: Comparing Forensic Psychiatric Patients and Correctional Offenders. International Journal of Forensic Mental Health 18:3, pages 243-259.
Read now
Read now
Gemma L. McKeon, Gail A. Robinson, Alexander E. Ryan, Stefan Blum, David Gillis, Carsten Finke & James G. Scott. (2018) Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review. Journal of Clinical and Experimental Neuropsychology 40:3, pages 234-252.
Read now
Read now
Davide Palumbo, Armida Mucci, Giuseppe Piegari, Valentina D’Alise, Annapaola Mazza & Silvana Galderisi. (2017) SoCIAL – training cognition in schizophrenia: a pilot study. Neuropsychiatric Disease and Treatment 13, pages 1947-1956.
Read now
Read now
Daniel J Foster, Derrick L Choi, P Jeffrey Conn & Jerri M Rook. (2014) Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia. Neuropsychiatric Disease and Treatment 10, pages 183-191.
Read now
Read now
Irina Rannikko, Liisa Paavola, Marianne Haapea, Sanna Huhtaniska, Jouko Miettunen, Juha Veijola, Graham
K. Murray, Anna Barnes, Karl-Erik Wahlberg, Matti Isohanni & Erika Jääskeläinen. (2012) Verbal learning and memory and their associations with brain morphology and illness course in schizophrenia spectrum psychoses. Journal of Clinical and Experimental Neuropsychology 34:7, pages 698-713.
Read now
Read now
Norio Yasui-Furukori. (2012) Update on the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Design, Development and Therapy 6, pages 107-115.
Read now
Read now
Meghan E Mcilwain, Jeff Harrison, Amanda J Wheeler & Bruce R Russell. (2011) Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatric Disease and Treatment 7, pages 135-149.
Read now
Read now
Articles from other publishers (156)
Zhinan Li, Zhuang Kang, Xiaowei Xia, Leijun Li, Junyan Wu, Jiamin Dai, Tong Liu, Cai Chen, Yong Qiu, Ming Chen, Yanxi Liu, Ziyi Zhang, Zili Han, Zhengjia Dai & Qinling Wei. (2024) Associations of resilience, white matter topological organization, and cognitive functions in first-episode, drug-naïve schizophrenia patients: A moderated mediation analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 128, pages 110867.
Crossref
Crossref
L.A Stabell, E. Johnsen, R. A Kroken, E.M. Løberg, A. Blindheim, I. Joa, S.K. Reitan, M. Rettenbacher, P. Munk-Jørgensen & R. Gjestad. (2023) Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial. BMC Psychiatry 23:1.
Crossref
Crossref
Kuppan Gokulakrishnan, Joyappa Nikhil, Biju Viswanath, Chinnasamy Thirumoorthy, Sandhya Narasimhan, Bharanidharan Devarajan, Ebin Joseph, Arul Kevin Daniel David, Sapna Sharma, Kavitha Vasudevan, Vanteemar S. Sreeraj, Bharath Holla, Venkataram Shivakumar, Monojit Debnath, Ganesan Venkatasubramanian & Shivarama Varambally. (2023) Comparison of gut microbiome profile in patients with schizophrenia and healthy controls - A plausible non-invasive biomarker?. Journal of Psychiatric Research 162, pages 140-149.
Crossref
Crossref
Stephanie Santarriaga, Kaia Gerlovin, Yasmine Layadi & Rakesh Karmacharya. (2023) Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review. Schizophrenia Research.
Crossref
Crossref
Saahithh Redddi Patlola, Gary Donohoe & Declan P. McKernan. (2023) The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 121, pages 110668.
Crossref
Crossref
Hehua Li, Hanqiu Li, Zhimin Zhu, Xiang Xiong, Yuanyuan Huang, Yangdong Feng, Zezhi Li, Kai Wu & Fengchun Wu. (2023) Association of serum homocysteine levels with intestinal flora and cognitive function in schizophrenia. Journal of Psychiatric Research 159, pages 258-265.
Crossref
Crossref
Mojtaba Oraki Kohshour, Eva C. Schulte, Urs Heilbronner, Monika Budde, Janos L. Kalman, Fanny Senner, Maria Heilbronner, Daniela Reich-Erkelenz, Sabrina K. Schaupp, Thomas Vogl, Kristina Adorjan, Ion-George Anghelescu, Volker Arolt, Bernhardt T. Baune, Udo Dannlowski, Detlef Dietrich, Andreas Fallgatter, Christian Figge, Markus Jäger, Fabian U. Lang, Georg Juckel, Carsten Konrad, Jens Reimer, Eva Z. Reininghaus, Max Schmauß, Carsten Spitzer, Martin von Hagen, Jens Wiltfang, Jörg Zimmermann, Till F.M. Andlauer, Markus M. Nöthen, Franziska Degenhardt, Andreas J. Forstner, Marcella Rietschel, Stephanie H. Witt, Andre Fischer, Peter Falkai, Sergi Papiol & Thomas G. Schulze. (2023) Association between mitochondria-related genes and cognitive performance in the PsyCourse Study. Journal of Affective Disorders 325, pages 1-6.
Crossref
Crossref
William N. Koller & Tyrone D. Cannon. (2023) Aberrant memory and delusional ideation: A pernicious partnership?. Clinical Psychology Review 99, pages 102231.
Crossref
Crossref
Huamin Liu, Zhiwei Huang, Xiaochun Zhang, Yong He, Shanyuan Gu, Dan Mo, Shaoli Wang, Zelin Yuan, Yining Huang, Qi Zhong, Rui Zhou, Keyi Wu, Fei Zou & Xianbo Wu. (2022) Association between lipid metabolism and cognitive function in patients with schizophrenia. Frontiers in Psychiatry 13.
Crossref
Crossref
Yuji Yamada, Takuma Inagawa, Naotsugu Hirabayashi & Tomiki Sumiyoshi. (2021) Emotion Recognition Deficits in Psychiatric Disorders as a Target of Non-invasive Neuromodulation: A Systematic Review. Clinical EEG and Neuroscience 53:6, pages 506-512.
Crossref
Crossref
Edward Millgate, Kira Griffiths, Alice Egerton, Eugenia Kravariti, Cecilia Casetta, Bill Deakin, Richard Drake, Oliver D Howes, Laura Kassoumeri, Sobia Khan, Steve Lankshear, Jane Lees, Shon Lewis, Elena Mikulskaya, Ebenezer Oloyede, Rebecca Owens, Rebecca Pollard, Nathalie Rich, Sophie Smart, Aviv Segev, Kyra Verena Sendt & James MacCabe. (2022) Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study. BMJ Open 12:11, pages e062570.
Crossref
Crossref
Mounica Reddy-Thootkur, Nina Vanessa Kraguljac & Adrienne Carol Lahti. (2022) The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders – A systematic review of magnetic resonance spectroscopy studies. Schizophrenia Research 249, pages 74-84.
Crossref
Crossref
Vasileios Siokas, Ioannis Liampas, Constantine G. Lyketsos & Efthimios Dardiotis. (2022) Association between Motor Signs and Cognitive Performance in Cognitively Unimpaired Older Adults: A Cross-Sectional Study Using the NACC Database. Brain Sciences 12:10, pages 1365.
Crossref
Crossref
Hayoung Ko, DongYeon Park, Jaehyun Shin, Rina Yu, Vin Ryu & Wonhye Lee. (2022) Cognitive profiles in bipolar I disorder and associated risk factors: Using Wechsler adult intelligence scale—IV. Frontiers in Psychology 13.
Crossref
Crossref
Seenae Eum, Scot Kristian Hill & Jeffrey R Bishop. (2022) Considering medication exposure in genomic association studies of cognition in psychotic disorders. Pharmacogenomics 23:14, pages 791-806.
Crossref
Crossref
Laura J. Benoit, Sarah Canetta & Christoph Kellendonk. (2022) Thalamocortical Development: A Neurodevelopmental Framework for Schizophrenia. Biological Psychiatry 92:6, pages 491-500.
Crossref
Crossref
Xiu R. Lowe, Maqdooda Merchant & Rachel A. Whitmer. (2022) Antipsychotic Medication Risk of Dementia and Death: A Propensity Matched Cohort Study. Current Drug Research Reviews 14:2, pages 139-147.
Crossref
Crossref
Dandan Wang, Ning Wei, Fangzhen Hu, Jianhua Li, Yucheng Wang, Zhiwei Qian, Miao Yang, Mingrong Yao, Yong Xia, Hong Yu, Wenzhen Tu, Minjie Ye, Cheng Qian, Jianbo Hu, Jingkai Chen, Chanchan Hu, Manli Huang, Yi Xu & Shaohua Hu. (2022) Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology 42:4, pages 383-390.
Crossref
Crossref
Yuji Yamada, Kazuki Sueyoshi, Yuma Yokoi, Takuma Inagawa, Naotsugu Hirabayashi, Hideki Oi, Aya Shirama & Tomiki Sumiyoshi. (2022) Transcranial Direct Current Stimulation on the Left Superior Temporal Sulcus Improves Social Cognition in Schizophrenia: An Open-Label Study. Frontiers in Psychiatry 13.
Crossref
Crossref
Petr Morozov, Roman Bekker & Youri Bykov. (2022) Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective. Frontiers in Psychiatry 13.
Crossref
Crossref
Davide Palumbo, Edoardo Caporusso, Giuseppe Piegari, Claudio Mencacci, Sara Torriero, Luigi Giuliani, Michele Fabrazzo, Dario Pinto & Silvana Galderisi. (2022) Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853). Frontiers in Psychiatry 13.
Crossref
Crossref
Oreoluwa O. Coker-Ayo, Samuel I. Nathaniel, Nicolas Poupore, Melissa J. Bailey-Taylor, Laurie Theriot Roley, Richard L. Goodwin, Brooks McPhail, Rebecca Russ-Sellers & Thomas I. Nathaniel. (2022) Sex Differences in Demographic and Pharmacological Factors in Alzheimer Patients With Dementia and Cognitive Impairments. Frontiers in Behavioral Neuroscience 16.
Crossref
Crossref
Lusi Zhang, Scot Kristian Hill, Bin Guo, Baolin Wu, Ney Alliey-Rodriguez, Seenae Eum, Paulo Lizano, Elena I. Ivleva, James L. Reilly, Richard S.E. Keefe, Sarah K. Keedy, Carol A. Tamminga, Godfrey D. Pearlson, Brett A. Clementz, Matcheri S. Keshavan, Elliot S. Gershon, John A. Sweeney & Jeffrey R. Bishop. (2022) Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 113, pages 110464.
Crossref
Crossref
Anaamika Campeau, Robert H. Mills, Toer Stevens, Leigh-Ana Rossitto, Michael Meehan, Pieter Dorrestein, Rebecca Daly, Tanya T. Nguyen, David J. Gonzalez, Dilip V. Jeste & Vivian Hook. (2021) Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia. Molecular Psychiatry 27:2, pages 1217-1225.
Crossref
Crossref
Animisha Singh, Vijay Kumar, Harsh Pathak, Arpitha A Jacob, Ganesan Venkatasubramanian, Shivarama Varambally & Naren P Rao. (2022) Effect of antipsychotic dose reduction on cognitive function in schizophrenia. Psychiatry Research 308, pages 114383.
Crossref
Crossref
Fernanda Crunfli, Caroline Brandão-Teles, Giuliana S. Zuccoli, Adriano J. M. Chaves Filho, Gabriela Maciel Vieira, Danyelle Silva-Amaral, José Alexandre Crippa, João F. C. Pedrazzi, Danielle S. Macêdo, Elaine Del-Bel & Felipe V. Gomes. 2022. Neuroproteomics as a Tool for Understanding Schizophrenia. Neuroproteomics as a Tool for Understanding Schizophrenia
15
33
.
Anika Poppe, Leonie Bais, Daniëlle van Duin, Branislava Ćurčić-Blake, Gerdina Hendrika Maria Pijnenborg & Lisette van der Meer. (2021) Improving cognition in severe mental illness by combining cognitive remediation and transcranial direct current stimulation: study protocol for a pragmatic randomized controlled pilot trial (HEADDSET). Trials 22:1.
Crossref
Crossref
Shen He, Yange Li, Tian Li, Feikang Xu, Duan Zeng, Yue Shi, Nan Zhao, Lei Zhang, Yin Zhu Ma, Qiang Wang, Wenjuan Yu, Yifeng Shen, Jingjing Huang & Huafang Li. (2021) Sex differences between serum total bilirubin levels and cognition in patients with schizophrenia. BMC Psychiatry 21:1.
Crossref
Crossref
James Maksymetz, Nellie E. Byun, Deborah J. Luessen, Brianna Li, Robert L. Barry, John C. Gore, Colleen M. Niswender, Craig W. Lindsley, Max E. Joffe & P. Jeffrey Conn. (2021) mGlu1 potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits. Cell Reports 37:5, pages 109950.
Crossref
Crossref
Samuel S. Newton & Monica Sathyanesan. (2021) Erythropoietin and Non-Erythropoietic Derivatives in Cognition. Frontiers in Pharmacology 12.
Crossref
Crossref
Marina P. Valerio, Alejandro G. Szmulewicz, Julieta Lomastro & Diego J. Martino. (2021) Neurocognitive performance in melancholic and non-melancholic major depressive disorder: A meta-analysis of comparative studies. Psychiatry Research 303, pages 114078.
Crossref
Crossref
Esther Setién-Suero, Víctor Ortiz-García de la Foz, Paula Suárez-Pinilla, Benedicto Crespo-Facorro & Rosa Ayesa-Arriola. (2021) Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison. Progress in Neuro-Psychopharmacology and Biological Psychiatry 110, pages 110309.
Crossref
Crossref
Guy M. WeissingerIIII, J. Margo Brooks Carthon, Charisse Ahmed & Bridgette M. Brawner. (2019) Experiences of Hospitalization of Patients With Psychotic Disorders on Medical–Surgical Units: A Thematic Analysis. Journal of the American Psychiatric Nurses Association 27:4, pages 306-321.
Crossref
Crossref
Qian Chen, Ting Cao, NaNa Li, Cuirong Zeng, Shuangyang Zhang, Xiangxin Wu, Bikui Zhang & Hualin Cai. (2021) Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders. Frontiers in Pharmacology 12.
Crossref
Crossref
Kiri T. Granger, Jennifer Ferrar, Sheryl Caswell, Mark Haselgrove, Paula M. Moran, Angela Attwood & Jennifer H. Barnett. (2021) Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition. Frontiers in Psychiatry 12.
Crossref
Crossref
Molly R. Lockington & Robert N. Hughes. (2020) Effects of olanzapine on anxiety-related behaviour in male and female rats assessed after 21–24 and 42–45 days of chronic treatment. Behavioural Pharmacology 32:2&3, pages 194-211.
Crossref
Crossref
Ting Cao, MiMi Tang, Pei Jiang, BiKui Zhang, XiangXin Wu, Qian Chen, CuiRong Zeng, NaNa Li, ShuangYang Zhang & HuaLin Cai. (2021) A Potential Mechanism Underlying the Therapeutic Effects of Progesterone and Allopregnanolone on Ketamine-Induced Cognitive Deficits. Frontiers in Pharmacology 12.
Crossref
Crossref
Jason M Noel & Cherry W Jackson. (2020) ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. American Journal of Health-System Pharmacy 77:24, pages 2114-2132.
Crossref
Crossref
Adrian Heald, Narges Azadbakht, Bethany Geary, Silke Conen, Helene Fachim, Dave Chi Hoo Lee, Nophar Geifman, Sanam Farman, Oliver Howes, Anthony Whetton & Bill Deakin. (2020) Application of SWATH mass spectrometry in the identification of circulating proteins does not predict future weight gain in early psychosis. Clinical Proteomics 17:1.
Crossref
Crossref
Marek Krzystanek, Krzysztof Krysta, Mariusz Borkowski, Katarzyna Skałacka, Jacek Przybyło, Artur Pałasz, Davor Mucic, Ewa Martyniak & Napoleon Waszkiewicz. (2020) The Effect of Smartphone-Based Cognitive Training on the Functional/Cognitive Markers of Schizophrenia: A One-Year Randomized Study. Journal of Clinical Medicine 9:11, pages 3681.
Crossref
Crossref
James E. Frampton. (2020) Lumateperone in schizophrenia: a profile of its use. Drugs & Therapy Perspectives 36:11, pages 477-484.
Crossref
Crossref
Rui Dong, Lian Yuan, Yong Yang, Xiang‐Dong Du, Qiufang Jia, Brett A. Dillon, Liling Yu & Xiang Yang Zhang. (2020) Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia. Human Psychopharmacology: Clinical and Experimental 35:6, pages 1-8.
Crossref
Crossref
Thomas Pokorny, Patricia Duerler, Erich Seifritz, Franz X. Vollenweider & Katrin H. Preller. (2019) LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychological Medicine 50:13, pages 2255-2264.
Crossref
Crossref
J. N. de Boer, A. E. Voppel, S. G. Brederoo, F. N. K. Wijnen & I. E. C. Sommer. (2020) Language disturbances in schizophrenia: the relation with antipsychotic medication. npj Schizophrenia 6:1.
Crossref
Crossref
Elysia Sokolenko, Jess Nithianantharajah & Nigel C. Jones. (2020) MK-801 impairs working memory on the Trial-Unique Nonmatch-to-Location test in mice, but this is not exclusively mediated by NMDA receptors on PV+ interneurons or forebrain pyramidal cells. Neuropharmacology 171, pages 108103.
Crossref
Crossref
Liang Shi & Clare M. Bergson. (2020) Neuregulin 1: an intriguing therapeutic target for neurodevelopmental disorders. Translational Psychiatry 10:1.
Crossref
Crossref
Kyna-Anne Conn, Thomas H. J. Burne & James P. Kesby. (2020) Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models. Frontiers in Neuroscience 14.
Crossref
Crossref
R. Kostova, R. Cecere, G. Thut & Peter J. Uhlhaas. (2020) Targeting cognition in schizophrenia through transcranial direct current stimulation: A systematic review and perspective. Schizophrenia Research 220, pages 300-310.
Crossref
Crossref
Yu. V. Bykov & R. A. Bekker. (2020) Electroconvulsive Therapy as a Corrector for Certain Side Effects of Antipsychotic Therapy. Acta Biomedica Scientifica (East Siberian Biomedical Journal) 5:2, pages 55-82.
Crossref
Crossref
Vanteemar S. Sreeraj, Anushree Bose, Harleen Chhabra, Venkataram Shivakumar, Sri Mahavir Agarwal, Janardhanan C. Narayanaswamy, Naren P. Rao, Muralidharan Kesavan, Shivarama Varambally & Ganesan Venkatasubramanian. (2020) Working memory performance with online-tDCS in schizophrenia: A randomized, double-blinded, sham-controlled, partial cross-over proof-of-concept study. Asian Journal of Psychiatry 50, pages 101946.
Crossref
Crossref
Tomasz Szeligowski, Alexandra Lim Yun, Belinda R. Lennox & Philip W. J. Burnet. (2020) The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications. Frontiers in Psychiatry 11.
Crossref
Crossref
B.C. Castelluccio, J.G. Kenney & J.K. Johannesen. (2020) Individual Alpha Peak Frequency Moderates Transfer of Learning in Cognitive Remediation of Schizophrenia. Journal of the International Neuropsychological Society 26:1, pages 19-30.
Crossref
Crossref
Jakub Staroń, Rafał Kurczab, Dawid Warszycki, Grzegorz Satała, Martyna Krawczyk, Ryszard Bugno, Tomasz Lenda, Piotr Popik, Adam S. Hogendorf, Agata Hogendorf, Krzysztof Dubiel, Mikołaj Matłoka, Rafał Moszczyński-Pętkowski, Jerzy Pieczykolan, Maciej Wieczorek, Paweł Zajdel & Andrzej J. Bojarski. (2020) Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties. European Journal of Medicinal Chemistry 185, pages 111857.
Crossref
Crossref
Neeti D. Mehta, Michelle J. Won, Shelly L. Babin, Saumil S. Patel, Adel A. Wassef, Alice Z. Chuang & Anne B. Sereno. (2019) Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings. Human Psychopharmacology: Clinical and Experimental 35:1.
Crossref
Crossref
Elysia Sokolenko, Matthew R Hudson, Jess Nithianantharajah & Nigel C Jones. (2019)
The mGluR
2/3
agonist LY379268 reverses NMDA receptor antagonist effects on cortical gamma oscillations and phase coherence, but not working memory impairments, in mice
. Journal of Psychopharmacology 33:12, pages 1588-1599.
Crossref
Crossref
Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, Jeremy S. Lum, Kelly A. Newell, Xu-Feng Huang & Katrina Weston-Green. (2019) Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 95, pages 109666.
Crossref
Crossref
Ferenc Zádor, Gábor Nagy-Grócz, Gabriella Kekesi, Szabolcs Dvorácskó, Edina Szűcs, Csaba Tömböly, Gyongyi Horvath, Sándor Benyhe & László Vécsei. (2019) Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. Molecules 24:20, pages 3709.
Crossref
Crossref
David Mothersill & Gary Donohoe. (2019) Neural Effects of Cognitive Training in Schizophrenia: A Systematic Review and Activation Likelihood Estimation Meta-analysis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 4:8, pages 688-696.
Crossref
Crossref
Alexander L Richards, Antonio F Pardiñas, Aura Frizzati, Katherine E Tansey, Amy J Lynham, Peter Holmans, Sophie E Legge, Jeanne E Savage, Ingrid Agartz, Ole A Andreassen, Gabriella A M Blokland, Aiden Corvin, Donna Cosgrove, Franziska Degenhardt, Srdjan Djurovic, Thomas Espeseth, Laura Ferraro, Charlotte Gayer-Anderson, Ina Giegling, Neeltje E van Haren, Annette M Hartmann, John J Hubert, Erik G Jönsson, Bettina Konte, Leonhard Lennertz, Loes M Olde Loohuis, Ingrid Melle, Craig Morgan, Derek W Morris, Robin M Murray, Håkan Nyman, Roel A Ophoff, Jim van Os, Tracey L Petryshen, Diego Quattrone, Marcella Rietschel, Dan Rujescu, Bart P F Rutten, Fabian Streit, Jana Strohmaier, Patrick F Sullivan, Kjetil Sundet, Michael Wagner, Valentina Escott-Price, Michael J Owen, Gary Donohoe, Michael C O’Donovan & James T R Walters. (2019) The Relationship Between Polygenic Risk Scores and Cognition in Schizophrenia. Schizophrenia Bulletin.
Crossref
Crossref
Yuji Yamada, Takuma Inagawa, Kazuki Sueyoshi, Norio Sugawara, Natsuki Ueda, Yoshie Omachi, Naotsugu Hirabayashi, Madoka Matsumoto & Tomiki Sumiyoshi. (2019) Social Cognition Deficits as a Target of Early Intervention for Psychoses: A Systematic Review. Frontiers in Psychiatry 10.
Crossref
Crossref
Lorenzo Del Fabro, Giuseppe Delvecchio, Armando D'Agostino & Paolo Brambilla. (2019) Effects of olanzapine during cognitive and emotional processing in schizophrenia: A review of functional magnetic resonance imaging findings. Human Psychopharmacology: Clinical and Experimental 34:3, pages e2693.
Crossref
Crossref
Merel Prikken, Mette J. Konings, Wan U. Lei, Marieke J.H. Begemann & Iris E.C. Sommer. (2019) The efficacy of computerized cognitive drill and practice training for patients with a schizophrenia-spectrum disorder: A meta-analysis. Schizophrenia Research 204, pages 368-374.
Crossref
Crossref
James E. Frampton. (2019) Brexpiprazole: A Review in Schizophrenia. Drugs 79:2, pages 189-200.
Crossref
Crossref
Jovan JavoracM.M., Gorana JanjićG.G., Dejan ŽivanovićB.B., Tijana JavoracM.M. & Ana MarkovićR.R.. (2019) The influence of typical and atypical antipsychotics on neurocognitive functions in patients with psychotic disorders. Hospital Pharmacology - International Multidisciplinary Journal 6:1, pages 765-773.
Crossref
Crossref
Meysam Amidfar, Young-Hoon Ko & Yong-Ku Kim. 2019. Frontiers in Psychiatry. Frontiers in Psychiatry
545
564
.
Marta Bosia, Mariachiara Buonocore, Margherita Bechi, Laura Santarelli, Marco Spangaro, Federica Cocchi, Carmelo Guglielmino, Laura Bianchi, Serena Bringheli, Francesca Bosinelli & Roberto Cavallaro. (2018) Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome. Frontiers in Psychiatry 9.
Crossref
Crossref
Courtney L.M. Nelson, Hayley M. Amsbaugh, James L. Reilly, Cherise Rosen, Robert W. Marvin, Michael E. Ragozzino, Jeffrey R. Bishop, John A. Sweeney & S. Kristian Hill. (2018) Beneficial and adverse effects of antipsychotic medication on cognitive flexibility are related to COMT genotype in first episode psychosis. Schizophrenia Research 202, pages 212-216.
Crossref
Crossref
Kathleen E. Wilson, Haley Demyanovich, Leah H. Rubin, Heidi J. Wehring, Catherine Kilday & Deanna L. Kelly. (2018) Relationship of Interferon-γ to Cognitive Function in Midlife Women with Schizophrenia. Psychiatric Quarterly 89:4, pages 937-946.
Crossref
Crossref
Julia M. Sheffield, Nicole R. Karcher & Deanna M. Barch. (2018) Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective. Neuropsychology Review 28:4, pages 509-533.
Crossref
Crossref
Yoshie Omachi & Tomiki Sumiyoshi. (2018) Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes. Frontiers in Psychiatry 9.
Crossref
Crossref
Jerri M. Rook, Jeanette L. Bertron, Hyekyung P. Cho, Pedro M. Garcia-Barrantes, Sean P. Moran, James T. Maksymetz, Kellie D. Nance, Jonathan W. Dickerson, Daniel H. Remke, Sichen Chang, Joel M. Harp, Anna L. Blobaum, Colleen M. Niswender, Carrie K. Jones, Shaun R. Stauffer, P. Jeffrey Conn & Craig W. Lindsley. (2018)
A Novel M
1
PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity
. ACS Chemical Neuroscience 9:9, pages 2274-2285.
Crossref
Crossref
Ching-En Lin, Chi-Hsiang Chung, Li-Fen Chen & Mei-Ju Chi. (2018) Increased risk of dementia in patients with Schizophrenia: A population-based cohort study in Taiwan. European Psychiatry 53, pages 7-16.
Crossref
Crossref
Agnieszka Nikiforuk. (2018) Assessment of cognitive functions in animal models of schizophrenia. Pharmacological Reports 70:4, pages 639-649.
Crossref
Crossref
Trevor C. Chopko & Craig W. Lindsley. (2018) Classics in Chemical Neuroscience: Risperidone. ACS Chemical Neuroscience 9:7, pages 1520-1529.
Crossref
Crossref
Sophie A. George, Mariana Rodriguez-Santiago, John Riley, James L. Abelson, Stan B. Floresco & Israel Liberzon. (2018) D-Cycloserine Facilitates Reversal in an Animal Model of Post-traumatic Stress Disorder. Behavioural Brain Research 347, pages 332-338.
Crossref
Crossref
Indrani Poddar, Patrick M. Callahan, Caterina M. Hernandez, Xiangkun Yang, Michael G. Bartlett & Alvin V. TerryJr.Jr.. (2018) Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine. Biochemical Pharmacology 151, pages 180-187.
Crossref
Crossref
Amalia Alexiadou, Vasilis P. Bozikas, Mary H. Kosmidis, Eleni Parlapani, Grigoris Kiosseoglou & Konstantinos Fokas. (2018) The effect of impaired verbal memory retrieval on autobiographical memory across different life periods in schizophrenia. Comprehensive Psychiatry 80, pages 81-88.
Crossref
Crossref
James M. Williams & George T. Grossberg. 2018. Clinical Psychopharmacology for Neurologists. Clinical Psychopharmacology for Neurologists
5
33
.
Anna Castañé & Albert Adell. 2018. 5-HT2A Receptors in the Central Nervous System. 5-HT2A Receptors in the Central Nervous System
191
204
.
Konstantinos N. Fountoulakis. (2017) Therapeutic effect of sertindole on neurocognitive deficit independently of positive and negative symptoms response: A case report. Psychiatry Research 258, pages 618-620.
Crossref
Crossref
Alexandra Pentaraki, Bello Utoblo & Eleni Maria Kokkoli. (2017) Cognitive remediation therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Maria Moscoso-Castro, Marc López-Cano, Irene Gracia-Rubio, Francisco Ciruela & Olga Valverde. (2017) Cognitive impairments associated with alterations in synaptic proteins induced by the genetic loss of adenosine A 2A receptors in mice. Neuropharmacology 126, pages 48-57.
Crossref
Crossref
Claire McGregor, Alexander Riordan & Janice Thornton. (2017) Estrogens and the cognitive symptoms of schizophrenia: Possible neuroprotective mechanisms. Frontiers in Neuroendocrinology 47, pages 19-33.
Crossref
Crossref
Sara Anna Bonini, Andrea Mastinu, Giulia Ferrari-Toninelli & Maurizio Memo. (2017) Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders. International Journal of Molecular Sciences 18:8, pages 1627.
Crossref
Crossref
Xian-Bin Li, Qi-Jing Bo, Guang-Ping Zhang, Wei Zheng, Zhi-Min Wang, An-Ning Li, Qing Tian, Jin-Tong Liu, Yi-Lang Tang & Chuan-Yue Wang. (2017) Effect of childhood trauma on cognitive functions in a sample of Chinese patients with schizophrenia. Comprehensive Psychiatry 76, pages 147-152.
Crossref
Crossref
M. Szlachta, P. Pabian, M. Kuśmider, J. Solich, M. Kolasa, D. Żurawek, M. Dziedzicka-Wasylewska & A. Faron-Górecka. (2017) Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice. Psychopharmacology 234:14, pages 2103-2112.
Crossref
Crossref
Dora Matzke, Matthew Hughes, Johanna C. Badcock, Patricia Michie & Andrew Heathcote. (2017) Failures of cognitive control or attention? The case of stop-signal deficits in schizophrenia. Attention, Perception, & Psychophysics 79:4, pages 1078-1086.
Crossref
Crossref
Timothy P. Rutkowski, Jason P. Schroeder, Georgette M. Gafford, Stephen T. Warren, David Weinshenker, Tamara Caspary & Jennifer G. Mulle. (2017) Unraveling the genetic architecture of copy number variants associated with schizophrenia and other neuropsychiatric disorders. Journal of Neuroscience Research 95:5, pages 1144-1160.
Crossref
Crossref
Lingzhi Wu, Xiaowen Feng, Tingting Li, Baojuan Sun, Muhammad Zahid Khan & Ling He. (2017) Risperidone ameliorated Aβ1-42-induced cognitive and hippocampal synaptic impairments in mice. Behavioural Brain Research 322, pages 145-156.
Crossref
Crossref
Z. D. Kabir, A. S. Lee & A. M. Rajadhyaksha. (2016)
L-type Ca
2+
channels in mood, cognition and addiction: integrating human and rodent studies with a focus on behavioural endophenotypes
. The Journal of Physiology 594:20, pages 5823-5837.
Crossref
Crossref
Hui Lin Ong, Mythily Subramaniam, Edimansyah Abdin, Peizhi Wang, Janhavi Ajit Vaingankar, Siau Pheng Lee, Saleha Shafie, Esmond Seow & Siow Ann Chong. (2016) Performance of Mini-Mental State Examination (MMSE) in long-stay patients with schizophrenia or schizoaffective disorders in a psychiatric institute. Psychiatry Research 241, pages 256-262.
Crossref
Crossref
Agnieszka A. Kaczor, Katarzyna M. Targowska-Duda, Barbara Budzyńska, Grażyna Biała, Andrea G. Silva & Marián Castro. (2016) In vitro, molecular modeling and behavioral studies of 3-{[4-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl}-1,2-dihydroquinolin-2-one (D2AAK1) as a potential antipsychotic. Neurochemistry International 96, pages 84-99.
Crossref
Crossref
Yu Xue, Jingshu Tang, Xiaozhuo Ma, Qing Li, Bingxue Xie, Yuchen Hao, Hongwei Jin, Kewei Wang, Guisen Zhang, Liangren Zhang & Lihe Zhang. (2016) Synthesis and biological activities of indolizine derivatives as alpha-7 nAChR agonists. European Journal of Medicinal Chemistry 115, pages 94-108.
Crossref
Crossref
Qisheng Zhong, Lingling Shen, Jiaqi Liu, Dianbao Yu, Simin Li, Zhiru Li, Jinting Yao, Taohong Huang, Shin-ichi Kawano, Yuki Hashi & Ting Zhou. (2016) Automatic on-line solid-phase extraction with ultra-high performance liquid chromatography and tandem mass spectrometry for the determination of ten antipsychotics in human plasma. Journal of Separation Science 39:11, pages 2129-2137.
Crossref
Crossref
Vinay Parikh, Munir Gunes Kutlu & Thomas J. Gould. (2016) nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. Schizophrenia Research 171:1-3, pages 1-15.
Crossref
Crossref
Dorota Frydecka, Jan Aleksander Beszłej, Piotr Gościmski, Andrzej Kiejna & Błażej Misiak. (2016) Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Research 235, pages 133-138.
Crossref
Crossref
Marta Bosia, Alessandro Pigoni, Laura Zagato, Lino Merlino, Nunzia Casamassima, Cristina Lorenzi, Adele Pirovano, Enrico Smeraldi, Paolo Manunta & Roberto Cavallaro. (2016) ADDing a piece to the puzzle of cognition in schizophrenia. European Journal of Medical Genetics 59:1, pages 26-31.
Crossref
Crossref
Diana Rofail, Antoine Regnault, Stéphanie le Scouiller, Carmen Galani Berardo, Daniel Umbricht & Ray Fitzpatrick. (2015) Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin. Quality of Life Research 25:1, pages 201-211.
Crossref
Crossref
Valerie M. Anderson, Meghan E. McIlwain, Robert R. Kydd & Bruce R. Russell. (2015) Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?. Psychiatry Research 230:3, pages 811-818.
Crossref
Crossref
A.B. Shmukler, I.Y. Gurovich, M. Agius & Y. Zaytseva. (2015) Long-term trajectories of cognitive deficits in schizophrenia: A critical overview. European Psychiatry 30:8, pages 1002-1010.
Crossref
Crossref
Alfredo Spagna, Yi Dong, Melissa-Ann Mackie, Ming Li, Philip D. Harvey, Yanghua Tian, Kai Wang & Jin Fan. (2015) Clozapine improves the orienting of attention in schizophrenia. Schizophrenia Research 168:1-2, pages 285-291.
Crossref
Crossref
Dylan M. Smith, Derek Fisher, Pierre Blier, Vadim Ilivitsky & Verner Knott. (2015) The separate and combined effects of monoamine oxidase A inhibition and nicotine on the mismatch negativity event related potential. Pharmacology Biochemistry and Behavior 137, pages 44-52.
Crossref
Crossref
Veena Kumari, Ulrich Ettinger, Seoung Eun Lee, Christine Deuschl, Anantha P. Anilkumar, Anne Schmechtig, Philip J. Corr, Dominic H. ffytche & Steven C. R. Williams. (2015) Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study. Psychopharmacology 232:17, pages 3135-3147.
Crossref
Crossref
Sol Fernandez-Gonzalo, Marc Turon, Merce Jodar, Esther Pousa, Carla Hernandez Rambla, Rebeca García & Diego Palao. (2015) A new computerized cognitive and social cognition training specifically designed for patients with schizophrenia/schizoaffective disorder in early stages of illness: A pilot study. Psychiatry Research 228:3, pages 501-509.
Crossref
Crossref
James N. Samson & Albert H. C. Wong. 2015. Drug Discovery for Schizophrenia. Drug Discovery for Schizophrenia
1
27
.
R. E. Nielsen, S. Levander, G. Kjaersdam Telléus, S. O. W. Jensen, T. Østergaard Christensen & S. Leucht. (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatrica Scandinavica 131:3, pages 185-196.
Crossref
Crossref
R. Bordet. (2015) Quels critères pour un traitement antipsychotique idéal ?. L'Encéphale 41:1, pages 39-46.
Crossref
Crossref
BS Chavan & Subhash Das. (2015) Is psychiatry intervention in Indian setting complete?. Indian Journal of Psychiatry 57:4, pages 345.
Crossref
Crossref
Naoki Hashimoto, Atsuhito Toyomaki, Minoru Honda, Satoru Miyano, Nobuyuki Nitta, Hiroyuki Sawayama, Yasufumi Sugawara, Keiichi Uemura, Noriko Tsukamoto, Tsukasa Koyama & Ichiro Kusumi. (2015) Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study. Annals of General Psychiatry 14:1, pages 1.
Crossref
Crossref
Mayako Yamazaki, Katsuya Harada, Noriyuki Yamamoto, Junko Yarimizu, Mayuko Okabe, Takeshi Shimada, Keni Ni & Nobuya Matsuoka. (2014) ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia. European Neuropsychopharmacology 24:10, pages 1698-1708.
Crossref
Crossref
Dawn Bruijnzeel, Uma Suryadevara & Rajiv Tandon. (2014) Antipsychotic treatment of schizophrenia: An update. Asian Journal of Psychiatry 11, pages 3-7.
Crossref
Crossref
Anders Lillevik Thorsen, Kyrre Johansson & Else-Marie Løberg. (2014) Neurobiology of Cognitive Remediation Therapy for Schizophrenia: A Systematic Review. Frontiers in Psychiatry 5.
Crossref
Crossref
Aikaterini Dalagdi, Aikaterini Arvaniti, John Papatriantafyllou, Kiriakos Xenitidis, Maria Samakouri & Miltos Livaditis. (2013) Psychosocial support and cognitive deficits in adults with schizophrenia. International Journal of Social Psychiatry 60:5, pages 417-425.
Crossref
Crossref
J Tian, W Wang, L Ye, X Cen, X Guan, J Zhang, P Yu, G Du, W Liu & Y Li. (2013) A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs. Human & Experimental Toxicology 33:5, pages 473-487.
Crossref
Crossref
James L. Reilly & John A. Sweeney. (2014) Generalized and Specific Neurocognitive Deficits in Psychotic Disorders: Utility for Evaluating Pharmacological Treatment Effects and as Intermediate Phenotypes for Gene Discovery. Schizophrenia Bulletin 40:3, pages 516-522.
Crossref
Crossref
Oliver Gruber, Antonella Chadha Santuccione & Helmut Aach. (2014) Magnetic Resonance Imaging in Studying Schizophrenia, Negative Symptoms, and the Glutamate System. Frontiers in Psychiatry 5.
Crossref
Crossref
Å tÄ›pán KubÃk, Helena BuchtováKarel ValeÅ¡AleÅ¡ StuchlÃk. (2014) MK-801 Impairs Cognitive Coordination on a Rotating Arena (Carousel) and Contextual Specificity of Hippocampal Immediate-Early Gene Expression in a Rat Model of Psychosis. Frontiers in Behavioral Neuroscience 8.
Crossref
Crossref
David M Dietz, Pamela J Kennedy, HaoSheng Sun, Ian Maze, Amy M Gancarz, Vincent Vialou, Ja Wook Koo, Ezekiell Mouzon, Subroto Ghose, Carol A Tamminga & Eric J Nestler. (2013) ΔFosB Induction in Prefrontal Cortex by Antipsychotic Drugs is Associated with Negative Behavioral Outcomes. Neuropsychopharmacology 39:3, pages 538-544.
Crossref
Crossref
Priscila Dib Gonçalves, Mariella Ometto, Gabriela Sendoya, Cristine Lacet, Luciana Monteiro & Paulo Jannuzzi Cunha. (2014) Neuropsychological Rehabilitation of Executive Functions: Challenges and Perspectives. Journal of Behavioral and Brain Science 04:01, pages 27-32.
Crossref
Crossref
Xiaofeng Guo, Zhanchou Zhang, Qinling Wei, Hailong Lv, Renrong Wu & Jingping Zhao. (2013) The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry 13:1.
Crossref
Crossref
Elizabeth J. Hutchings, Jennifer L. Waller & Alvin V. TerryJr.Jr.. (2013) Differential Long-Term Effects of Haloperidol and Risperidone on the Acquisition and Performance of Tasks of Spatial Working and Short-Term Memory and Sustained Attention in Rats. Journal of Pharmacology and Experimental Therapeutics 347:3, pages 547-556.
Crossref
Crossref
S. Kristian Hill, Olivia Bjorkquist, Tarra Carrathers, Jarett E. Roseberry, William C. Hochberger & Jeffrey R. Bishop. (2013) Sequential processing deficits in schizophrenia: Relationship to neuropsychology and genetics. Schizophrenia Research 151:1-3, pages 91-96.
Crossref
Crossref
Quincy J.J. Wong, Marta Miller, Ann Fiorito & Juelyn Ireland. (2013) A snapshot of cognitive functioning: Deriving a tool for the efficient assessment of cognition in schizophrenia and other chronic psychiatric disorders in a real-world inpatient setting. Psychiatry Research 210:2, pages 375-380.
Crossref
Crossref
Sabrina Schneider, Thomas Juergen Bahmer, Florian Gerhard Metzger, Andreas Reif, Thomas Polak, Bruno Pfuhlmann, Gudrun Walter, Mark-Christian Eberle, Lena Helene Ernst, Andreas Jochen Fallgatter & Ann-Christine Ehlis. (2013) Quetiapine and flupentixol differentially improve anterior cingulate cortex function in schizophrenia patients: an event-related potential study. International Journal of Neuropsychopharmacology 16:9, pages 1911-1925.
Crossref
Crossref
Qingqing Xu, Xi Wu, Yuyu Xiong, Qinghe Xing, Lin He & Shengying Qin. (2013) Pharmacogenomics can improve antipsychotic treatment in schizophrenia. Frontiers of Medicine 7:2, pages 180-190.
Crossref
Crossref
Michael F. Egan, Xin Zhao, Regina Gottwald, Lyn Harper-Mozley, Ying Zhang, Duane Snavely, Christopher Lines & David Michelson. (2013) Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophrenia Research 146:1-3, pages 224-230.
Crossref
Crossref
Elise Demeter, Sally K. Guthrie, Stephan F. Taylor, Martin Sarter & Cindy Lustig. (2013) Increased distractor vulnerability but preserved vigilance in patients with schizophrenia: Evidence from a translational Sustained Attention Task. Schizophrenia Research 144:1-3, pages 136-141.
Crossref
Crossref
Tara M. Brinkman, Nan Zhang, Nicole J. Ullrich, Pim Brouwers, Daniel M. Green, Deo Kumar Srivastava, Lonnie K. Zeltzer, Marilyn Stovall, Leslie L. Robison & Kevin R. Krull. (2012) Psychoactive medication use and neurocognitive function in adult survivors of childhood cancer: A report from the childhood cancer survivor study. Pediatric Blood & Cancer 60:3, pages 486-493.
Crossref
Crossref
Roger S. McIntyre, Alissa M. Powell, Oksana Kaidanovich-Beilin, Joanna K. Soczynska, Mohammad Alsuwaidan, Hanna O. Woldeyohannes, Ashley S. Kim & L. Ashley Gallaugher. (2013) The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behavioural Brain Research 237, pages 164-171.
Crossref
Crossref
P. Valsecchi, F. Bettini & E. Tamussi. 2013. La riabilitazione cognitiva della schizofrenia. La riabilitazione cognitiva della schizofrenia
37
45
.
Yoshio Kaneko & Matcheri Keshavan. (2012) Cognitive Remediation in Schizophrenia. Clinical Psychopharmacology and Neuroscience 10:3, pages 125-135.
Crossref
Crossref
S Miyamoto, N Miyake, L F Jarskog, W W Fleischhacker & J A Lieberman. (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry 17:12, pages 1206-1227.
Crossref
Crossref
Barbara Remberk, Irena Namysłowska & Filip Rybakowski. (2012) Cognition and communication dysfunctions in early-onset schizophrenia: Effect of risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry 39:2, pages 348-354.
Crossref
Crossref
V. V. Dias, V. Balanzá‐Martinez, M. G. Soeiro‐de‐Souza, R. A. Moreno, M. L. Figueira, R. Machado‐Vieira & E. Vieta. (2012) Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatrica Scandinavica 126:5, pages 315-331.
Crossref
Crossref
. 2012. Qu'est-ce que les psychoses ?. Qu'est-ce que les psychoses ?
99
125
.
Heekyung Lee, Dino Dvorak, Hsin-Yi Kao, Áine M. Duffy, Helen E. Scharfman & André A. Fenton. (2012) Early Cognitive Experience Prevents Adult Deficits in a Neurodevelopmental Schizophrenia Model. Neuron 75:4, pages 714-724.
Crossref
Crossref
R. E. Nielsen, S. Levander, D. Thode & J. Nielsen. (2012) Effects of sertindole on cognition in clozapine‐treated schizophrenia patients. Acta Psychiatrica Scandinavica 126:1, pages 31-39.
Crossref
Crossref
C. O. Akagbosu, G. C. Evans, D. Gulick, R. F. Suckow & D. J. Bucci. (2010) Exposure to Kynurenic Acid During Adolescence Produces Memory Deficits in Adulthood. Schizophrenia Bulletin 38:4, pages 769-778.
Crossref
Crossref
Norio Yasui-Furukori, Ayako Kaneda, Norio Sugawara, Tetsu Tomita & Sunao Kaneko. (2011) Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. Journal of Psychopharmacology 26:6, pages 806-812.
Crossref
Crossref
Lauren M. Ellman, Sophia Vinogradov, William S. Kremen, John H. Poole, David M. Kern, Raymond F. Deicken & Alan S. Brown. (2012) Low maternal hemoglobin during pregnancy and diminished neuromotor and neurocognitive performance in offspring with schizophrenia. Schizophrenia Research 138:1, pages 81-87.
Crossref
Crossref
Yi-Ting Lin, Chih-Min Liu, Ming-Jang Chiu, Chen-Chung Liu, Yi-Ling Chien, Tzung-Jeng Hwang, Fu-Shan Jaw, Jia-Chi Shan, Ming H. Hsieh & Hai-Gwo Hwu. (2012) Differentiation of Schizophrenia Patients from Healthy Subjects by Mismatch Negativity and Neuropsychological Tests. PLoS ONE 7:4, pages e34454.
Crossref
Crossref
Christopher G. AhnAllen. (2012) The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia. Current Opinion in Psychiatry 25:2, pages 103-108.
Crossref
Crossref
Mark J. Millan, Yves Agid, Martin Brüne, Edward T. Bullmore, Cameron S. Carter, Nicola S. Clayton, Richard Connor, Sabrina Davis, Bill Deakin, Robert J. DeRubeis, Bruno Dubois, Mark A. Geyer, Guy M. Goodwin, Philip Gorwood, Thérèse M. Jay, Marian Joëls, Isabelle M. Mansuy, Andreas Meyer-Lindenberg, Declan Murphy, Edmund Rolls, Bernd Saletu, Michael Spedding, John Sweeney, Miles Whittington & Larry J. Young. (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery 11:2, pages 141-168.
Crossref
Crossref
J.-P. Olié. 2012. Manuel de psychiatrie. Manuel de psychiatrie
571
630
.
Daria Peleg-Raibstein, Joram Feldon & Urs Meyer. 2012. Current Antipsychotics. Current Antipsychotics
361
406
.
David L. McKinzie & Frank P. Bymaster. 2012. Novel Antischizophrenia Treatments. Novel Antischizophrenia Treatments
233
265
.
Tomomi Tenjin, Seiya Miyamoto, Nobumi Miyake, Shin Ogino, Rei Kitajima, Kazuaki Ojima, Jun Arai, Haruki Teramoto, Sachiko Tsukahara, Yukie Ito, Masanori Tadokoro, Kiriko Anai, Yasuyuki Funamoto, Yasuhiro Kaneda, Tomiki Sumiyoshi & Noboru Yamaguchi. (2012) Retracted: Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia. Human Psychopharmacology: Clinical and Experimental 27:1, pages 90-100.
Crossref
Crossref
Robert M. Bilder, Andrew Howe, Nic Novak, Fred W. Sabb & D. Stott Parker. (2011) The genetics of cognitive impairment in schizophrenia: a phenomic perspective. Trends in Cognitive Sciences 15:9, pages 428-435.
Crossref
Crossref
Matcheri S. Keshavan, Debra M. Montrose, Jean M. Miewald & Ripu D. Jindal. (2011) Sleep correlates of cognition in early course psychotic disorders. Schizophrenia Research 131:1-3, pages 231-234.
Crossref
Crossref
René Ernst Nielsen. (2011) Cognition in schizophrenia – a systematic review. Drug Discovery Today: Therapeutic Strategies 8:1-2, pages 43-48.
Crossref
Crossref
Rune Andersen, Birgitte Fagerlund, Hans Rasmussen, Bjorn H. Ebdrup, Bodil Aggernaes, Anders Gade, Bob Oranje & Birte Glenthoj. (2011) Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. Psychiatry Research 187:1-2, pages 49-54.
Crossref
Crossref
Dennis J. McKenna, Juan M. Ruiz, Thomas R. Hoye, Bryan L. Roth & Alan T. Shoemaker. (2011) Receptor screening technologies in the evaluation of Amazonian ethnomedicines with potential applications to cognitive deficits. Journal of Ethnopharmacology 134:2, pages 475-492.
Crossref
Crossref
Maria L Figueira & Sofia Brissos. (2011) Measuring psychosocial outcomes in schizophrenia patients. Current Opinion in Psychiatry, pages 1.
Crossref
Crossref
Miodrag Milenovic, Nevena Kalezic, Dusica Simic, Draga Dimitrijevic, Dejan Markovic & Ivan Dimitrijevic. (2011) Preoperative assessment and management of patient with psychiatric comorbidity. Acta chirurgica Iugoslavica 58:2, pages 143-149.
Crossref
Crossref
Rajiv Tandon, Henry A. Nasrallah & Matcheri S. Keshavan. (2010) Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. Schizophrenia Research 122:1-3, pages 1-23.
Crossref
Crossref
M. Riedel, R. Schennach‐Wolff, R. Musil, S. Dehning, A. Cerovecki, M. Opgen‐Rhein, J. Matz, F. Seemüller, M. Obermeier, R. R. Engel, N. Müller, H.‐J. Möller & I. Spellmann. (2010) Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone. Human Psychopharmacology: Clinical and Experimental 25:2, pages 116-125.
Crossref
Crossref